RESUMO
Some case reports mention that Spironolactone, a mineral corticoid antagonist and aldosterone antagonist, reduces binging in patients with bulimia nervosa. Therefore, we decided to study these findings by using a randomized, double-blind, placebo controlled study design. In one study arm, patients with bulimia nervosa were treated with 150 mg Spironolactone per day; in the other arm, patients received a placebo for a total of 8 weeks. The target variables were the number of binges and the bulimia scale of the Eating Disorder Inventory. The study included 93 patients. The results show that the number of binges and the scores on the bulimia scale decreased somewhat, but this occurred in both groups. We were not able to show any significant statistical differences between the Spironolactone group and the placebo group. Additional evaluations, executed with data from the Symptom-Check-List (SCL-90R) and with other scales from the EDI-2 also showed no effect of Spironolactone. Therefore, a treatment with Spironolactone seems to have no effect on bulimia nervosa symptoms.
Assuntos
Bulimia Nervosa/tratamento farmacológico , Bulimia Nervosa/psicologia , Antagonistas de Receptores de Mineralocorticoides/uso terapêutico , Espironolactona/uso terapêutico , Adulto , Método Duplo-Cego , Feminino , Humanos , Antagonistas de Receptores de Mineralocorticoides/administração & dosagem , Antagonistas de Receptores de Mineralocorticoides/efeitos adversos , Espironolactona/administração & dosagem , Espironolactona/efeitos adversosAssuntos
Bulimia Nervosa/tratamento farmacológico , Espironolactona/uso terapêutico , Adulto , Bulimia Nervosa/patologia , Manual Diagnóstico e Estatístico de Transtornos Mentais , Método Duplo-Cego , Feminino , Humanos , Pessoa de Meia-Idade , Antagonistas de Receptores de Mineralocorticoides/administração & dosagem , Antagonistas de Receptores de Mineralocorticoides/uso terapêutico , Mineralocorticoides/administração & dosagem , Mineralocorticoides/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , Espironolactona/administração & dosagem , Falha de TratamentoRESUMO
OBJECTIVES: Calcitonin (CT) has a regulative function in calcium (Ca) transfer from mother to the fetus. There are indications that cholecalciferol can play a role in this process. With this background, the effect of 24, 25-dihydroxycholecalciferol (24, 25-DHC) on immunoreactive CT by human placenta at term was studied in vitro. METHODS: Placental tissue samples were incubated in culture medium with normal total Ca (1.3 mM) concentrations during 6 hours at 37 degrees C. 24, 25-DHC was added to the samples. RESULTS: Addition of 24, 25-DHC in concentrations of 25, 75 and 150 pg/ml was followed by a significant decrease of CT levels in medium. The concentrations decreased from 100% (basis value after 2 hours) to 31%, 46% and 49% respectively. CONCLUSION: Probably 24, 25-DHC has a modulating effect on the regulation of placental Ca transfer by CT.
